CHICAGO , Aug. 14, 2024 /PRNewswire/ -- The global hematology analyzers and reagents market is expected to grow from USD 6.6 billion in 2024 to USD 8.
8 billion by 2029, at a CAGR of 6.1%, driven by advancements in technology, an increase in blood disorder incidences, and the integration of flow cytometry with hematology analyzers. Key market drivers include rising technological innovations, such as new high-throughput platforms and fully automated systems by companies like HORIBA and Siemens Healthineers.
However, growth is restrained by high costs and the slow adoption of advanced instruments in emerging economies, compounded by a shortage of skilled professionals. Opportunities for expansion exist in emerging markets with improving healthcare infrastructure and rising expenditures. North America leads the market due to high demand for blood components, while the Asia-Pacific region is anticipated to experience the most significant growth.
Major players include Sysmex, Danaher, and Siemens Healthineers, with recent developments focusing on new product launches and partnerships..